Henrik Schmidt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Henrik Schmidt has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Boe Sandahl Sorensen
Department of Clinical Biochemistry, Aarhus University Hospital, 8200 Aarhus, Denmark
2 shared publications C Bang
1 shared publicationC. Rytter
1 shared publicationEbba Nexo
1 shared publication- Ebba Nexo
Aarhus University Hospital
1 shared publication H von der Maase
1 shared publication
Latest Publications
- 1 June 2004
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 14 (3) , 211-215
S100β protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma
The aim of this study was to evaluate the biological variation in the serum level of S100beta protein in untreated patients with metastatic melanoma and to use this variation to subsequently evaluate serum levels as a method of monitoring objective response to interleukin-2 (IL2) based treatment. Such an approach has not, to our knowledge, been published previously. Consecutive blood samples were collected before, during and after treatment and in the follow-up period from 66 patients treated with IL2-based immunotherapy. In 11 of these patients, a further three samples were drawn on each of 3 days prior to treatment to evaluate the variation in S100beta. This variation was later used to distinguish between increased, unchanged or decreased S100beta levels during treatment. We observed a significant association between changes in S100beta levels and clinical outcome after the first and second treatment cycles. All responding patients had a decline in S100beta levels or normal values during the first cycle. Changes in S100beta levels after the first cycle and the type of treatment were independent predictive factors for the clinical outcome in multivariate analysis. In conclusion, increasing S100beta values were independently associated with progressive disease, and our data suggest that significant changes in S100beta levels may be valuable for monitoring and predicting clinical outcome during IL2-based immunotherapy and chemoimmunotherapy.
- 1 June 2004
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 14 (3) , 211-215
S100β protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma
The aim of this study was to evaluate the biological variation in the serum level of S100beta protein in untreated patients with metastatic melanoma and to use this variation to subsequently evaluate serum levels as a method of monitoring objective response to interleukin-2 (IL2) based treatment. Such an approach has not, to our knowledge, been published previously. Consecutive blood samples were collected before, during and after treatment and in the follow-up period from 66 patients treated with IL2-based immunotherapy. In 11 of these patients, a further three samples were drawn on each of 3 days prior to treatment to evaluate the variation in S100beta. This variation was later used to distinguish between increased, unchanged or decreased S100beta levels during treatment. We observed a significant association between changes in S100beta levels and clinical outcome after the first and second treatment cycles. All responding patients had a decline in S100beta levels or normal values during the first cycle. Changes in S100beta levels after the first cycle and the type of treatment were independent predictive factors for the clinical outcome in multivariate analysis. In conclusion, increasing S100beta values were independently associated with progressive disease, and our data suggest that significant changes in S100beta levels may be valuable for monitoring and predicting clinical outcome during IL2-based immunotherapy and chemoimmunotherapy.
- Open Access
- 1 December 2002
- Published by Elsevier in Annals of Oncology
- Vol. 13 (12) , 1919-1924
A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-α in patients with metastatic melanoma
Background: Experimental data had suggested a synergistic effect of histamine with interleukin-2 (IL-2) and interferon-α (IFN-α). Patients and methods: Forty-one patients with metastatic melanoma received IL-2 9 MU subcutaneously (s.c.) twice daily on days 4–8 and 25–29, and once daily on days 11–15 and 32–36. IFN-α-2b was given as 5 MU s.c. on days 1–3 and then daily to day 43. Histamine 1 mg s.c. was administered twice daily, following IL-2 and IFN injections starting on day 4. Efficacy and toxicity were compared with those of 42 patients included on exactly the same criteria and receiving the same regimen but without histamine. Results: Two patients achieved a partial response (PR) for an objective response rate of 5% [95% confidence interval (CI) 1% to 17%]. Median overall survival was 7.8 months (95% CI 6.4–9.1). In the control group, two complete responses and one PR were achieved. Median overall survival was 7.1 months (95% CI 5.4–8.9). Conclusions: This IL-2 and IFN regimen was well tolerated on an outpatient basis. However, the applied regimen cannot be recommended because of the low clinical efficacy. Histamine did not add efficacy or toxicity in combination with this moderate-dose schedule of IL-2 and IFN.
- 1 December 2002
- Published by Elsevier in Annals of Oncology
- Vol. 13 (12) , 1919-1924
Open AccessA phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-α in patients with metastatic melanoma
Background: Experimental data had suggested a synergistic effect of histamine with interleukin-2 (IL-2) and interferon-α (IFN-α). Patients and methods: Forty-one patients with metastatic melanoma received IL-2 9 MU subcutaneously (s.c.) twice daily on days 4–8 and 25–29, and once daily on days 11–15 and 32–36. IFN-α-2b was given as 5 MU s.c. on days 1–3 and then daily to day 43. Histamine 1 mg s.c. was administered twice daily, following IL-2 and IFN injections starting on day 4. Efficacy and toxicity were compared with those of 42 patients included on exactly the same criteria and receiving the same regimen but without histamine. Results: Two patients achieved a partial response (PR) for an objective response rate of 5% [95% confidence interval (CI) 1% to 17%]. Median overall survival was 7.8 months (95% CI 6.4–9.1). In the control group, two complete responses and one PR were achieved. Median overall survival was 7.1 months (95% CI 5.4–8.9). Conclusions: This IL-2 and IFN regimen was well tolerated on an outpatient basis. However, the applied regimen cannot be recommended because of the low clinical efficacy. Histamine did not add efficacy or toxicity in combination with this moderate-dose schedule of IL-2 and IFN.
- 1 December 2002
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 12 (6) , 585-592
Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma
Circulating malignant cells in peripheral blood are thought to be precursors and surrogate markers of distant metastases and hence markers of a poor clinical outcome. In this study, we used the detection of MART-1 and tyrosinase (TYR) mRNA with a quantitative reverse transcription-polymerase chain reaction (RT-PCR) assay to identify circulating melanoma cells. Blood samples were obtained from 35 patients with metastatic melanoma before, during and after treatment with interleukin-2, interferon-α and cisplatin. In addition, MART-1 and TYR protein was identified by immunohistochemistry in consecutive biopsies from 15 of the patients. Analysis of three daily blood samples for 3 days demonstrated that four out of 11 patients examined were negative for both markers on all occasions, and two patients were positive for both markers on all occasions but one. The remaining five patients showed sporadic low positive results for one or the other of the two markers. By comparing the immunohistochemistry results from consecutive biopsies with the RT-PCR results, we demonstrated that patients with MART-1 and TYR protein in their tumour cells had circulating MART-1 and TYR mRNA in 77% and 54% of the cases, respectively. During treatment, the majority of patients who were positive for MART-1 and TYR mRNA converted to being negative. However, these conversions did not significantly correlate with objective response. The presence of TYR mRNA in one of the first two samples showed a trend towards being an independent prognostic factor for poor survival.
- 1 December 2002
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 12 (6) , 585-592
Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma
Circulating malignant cells in peripheral blood are thought to be precursors and surrogate markers of distant metastases and hence markers of a poor clinical outcome. In this study, we used the detection of MART-1 and tyrosinase (TYR) mRNA with a quantitative reverse transcription-polymerase chain reaction (RT-PCR) assay to identify circulating melanoma cells. Blood samples were obtained from 35 patients with metastatic melanoma before, during and after treatment with interleukin-2, interferon-α and cisplatin. In addition, MART-1 and TYR protein was identified by immunohistochemistry in consecutive biopsies from 15 of the patients. Analysis of three daily blood samples for 3 days demonstrated that four out of 11 patients examined were negative for both markers on all occasions, and two patients were positive for both markers on all occasions but one. The remaining five patients showed sporadic low positive results for one or the other of the two markers. By comparing the immunohistochemistry results from consecutive biopsies with the RT-PCR results, we demonstrated that patients with MART-1 and TYR protein in their tumour cells had circulating MART-1 and TYR mRNA in 77% and 54% of the cases, respectively. During treatment, the majority of patients who were positive for MART-1 and TYR mRNA converted to being negative. However, these conversions did not significantly correlate with objective response. The presence of TYR mRNA in one of the first two samples showed a trend towards being an independent prognostic factor for poor survival.